1. National Cancer Institute, Tumor Markers, Data accesării: 20 martie 2018
  2. Bücheler M. et al. Personalised Medicine, in Europe- Enhancing Patient Access to Pharmaceutical Drug-Diagnostic Companion Products, Patient Access Study Nov. 2014. EPEMED White Paper, Charite, Berlin
  3. Strimbu et al. What are Biomarkers? Curr Opin HIV AIDS 2010;5:463-466
  4. Institutul Oncologic “Prof. Dr. Ioan Chiricuță”, Bro%C5%9Furi/00000772/0opmf_Cancerul%20Pulmonar.pdf
  5. Lung Cancer Alliance,
  6. Bray et all., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries; CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492
  7. The Global Cancer Observatory, ianuarie 2019 –
  8. Lung cancer alliance, Symptoms of lung cancer:
  9. American Cancer Society. Small Cell Lung Cancer Risk Factors. Available at:
  10. Societatea Americană de Cancer,
  12. Asociația internațională de studiu al cancerului,
  14. Carta Albă a Imuno-Oncologiei, InoMed 2018
  17. Cancer Research Institute. What is Cancer Immunotherapy? – cancer-immunotherapy
  18. ACS, Radiation Therapy – What it is, How it helps:
  21. Vargas et al. Biomarker development in the precision medicine era: lung cancer as a case study. Nature Reviews Cancer 2016;16:525-537
  23. DAKO: PD-L1 IHC 22C3 pharmDx product information ( ihc-22c3-pharmdx?set-Country=true&purl=ar39/, accessed on 20/12/2016)